Northwestern Mutual Wealth Management Co. Invests $4.27 Million in Edwards Lifesciences Corporation $EW

Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 47,155 shares of the medical research company's stock, valued at approximately $4,266,000.

Several other institutional investors have also added to or reduced their stakes in EW. Hanson & Doremus Investment Management purchased a new position in shares of Edwards Lifesciences in the first quarter valued at about $25,000. JPL Wealth Management LLC bought a new position in shares of Edwards Lifesciences during the third quarter valued at about $25,000. MV Capital Management Inc. purchased a new stake in shares of Edwards Lifesciences during the fourth quarter worth about $26,000. RMG Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences during the first quarter worth about $26,000. Finally, TrinityBridge Ltd bought a new stake in shares of Edwards Lifesciences in the second quarter worth about $27,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on EW. TD Cowen restated a "buy" rating on shares of Edwards Lifesciences in a report on Tuesday, July 21st. UBS Group started coverage on Edwards Lifesciences in a report on Tuesday, July 28th. They issued a "buy" rating and a $110.00 price objective for the company. Weiss Ratings reiterated a "hold (c)" rating on shares of Edwards Lifesciences in a research report on Friday, July 17th. JPMorgan Chase & Co. boosted their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the company an "overweight" rating in a research note on Friday, July 24th. Finally, Truist Financial upped their target price on Edwards Lifesciences from $90.00 to $95.00 and gave the company a "hold" rating in a report on Thursday, July 16th. Seventeen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $100.27.

Edwards Lifesciences Trading Up 0.1%

Shares of EW opened at $89.89 on Monday. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $96.29. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. The firm's 50-day moving average price is $89.21 and its 200-day moving average price is $84.68. The firm has a market capitalization of $51.76 billion, a price-to-earnings ratio of 51.66, a PEG ratio of 2.25 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.74 by $0.04. The company had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. Edwards Lifesciences's revenue was up 13.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Sell-side analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Insider Activity

In other news, VP Daniel J. Lippis sold 619 shares of the firm's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the transaction, the vice president owned 40,034 shares in the company, valued at $3,684,329.02. This trade represents a 1.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the sale, the senior vice president owned 15,334 shares in the company, valued at $1,319,950.72. This represents a 3.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 25,570 shares of company stock worth $2,219,390 in the last quarter. 0.31% of the stock is owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source